NovoCure Limited - Ordinary Shares (NVCR): Price and Financial Metrics
NovoCure Limited - Ordinary Shares (NVCR)
Today's Latest Price: $169.10 USD
Updated Jan 22 4:00pm
Add NVCR to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 239 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
NVCR Stock Summary
- NVCR's current price/earnings ratio is 913.42, which is higher than 98.87% of US stocks with positive earnings.
- Price to trailing twelve month operating cash flow for NVCR is currently 332.38, higher than 98.73% of US stocks with positive operating cash flow.
- Over the past twelve months, NVCR has reported earnings growth of -2,119.91%, putting it ahead of merely 1.03% of US stocks in our set.
- If you're looking for stocks that are quantitatively similar to NovoCure Ltd, a group of peers worth examining would be NUAN, GORO, KTOS, PODD, and CELH.
- To check out NovoCure Ltd's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001645113.
NVCR Stock Price Chart Interactive Chart >
NVCR Price/Volume Stats
| Current price | $169.10 | 52-week high | $182.74 |
| Prev. close | $171.84 | 52-week low | $53.40 |
| Day low | $167.83 | Volume | 263,300 |
| Day high | $172.95 | Avg. volume | 671,371 |
| 50-day MA | $152.51 | Dividend yield | N/A |
| 200-day MA | $100.29 | Market Cap | 17.21B |
NovoCure Limited - Ordinary Shares (NVCR) Company Bio
NovoCure Limited is a commercial stage oncology company which develops treatment for solid tumor cancers therapy called the tumor treating fields. The company was founded in 2000 and is based in Saint Helier, Channel Islands.
NVCR Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $169.10 | $7555.6 | 4297% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for NovoCure Ltd. To summarize, we found that NovoCure Ltd ranked in the 95th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 4318.5%. The most interesting components of our discounted cash flow analysis for NovoCure Ltd ended up being:
- In the past 1.5 years, NovoCure Ltd has a compound free cash flow growth rate of 3.93%; that's higher than 95.1% of free cash flow generating stocks in the Healthcare sector.
- The business' balance sheet reveals debt to be 0% of the company's capital (with equity being the remaining amount). Approximately merely 2.19% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
- NovoCure Ltd's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than only 0% of US stocks with positive free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 4211% |
| 1% | 4254% |
| 2% | 4297% |
| 3% | 4340% |
| 4% | 4383% |
| 5% | 4426% |
MNKKQ, CYH, AMEH, RDY, and BEAT can be thought of as valuation peers to NVCR, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...